Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Authors: Liping Han, Qiufang Jiang, Wei Yao, Tian Fu, Qingdi Zeng

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection.

Methods

We searched these studies from medical electronic database. A total of 18 studies that met the inclusion criteria were recruited in this meta-analysis. Pooled odds ratios (OR) with 95% confidence intervals (CI) were determined by the fixed effects model of meta-analysis.

Results

The objective response rate (ORR) and disease control rate (DCR) of cisplatin plus IL-2 for controlling MPE was significantly higher than that of cisplatin alone (p < 0.001). In addition, compared with cisplatin alone, the presence of IL-2 improved the quality of life (QOL) of patients with MPE (p < 0.001). Although the use of IL-2 seemed to increase the probability of fever in patients (p = 0.001), it did not lead to extra other side effects (AEs) including myelotoxicity, nausea/vomiting and chest pain (p > 0.05).

Conclusions

The low-dose IL-2 improved the ORR, DCR and QOL of patients in the treatment of MPE. Although it may cause fever in patients, it did not increase other AEs.
Literature
1.
Biaoxue R, Hui P, Wenlong G, Shuanying Y. Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion. Sci Rep. 2016;6:39355.CrossRefPubMedPubMedCentral
2.
Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res. 2017;9:229–41.CrossRefPubMedPubMedCentral
3.
Biaoxue R, Shuxia M, Wenlong G, Shuanying Y. Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions. World J Surg Oncol. 2015;13:329.CrossRefPubMedPubMedCentral
4.
Rong B, Zhao C, Gao W, Yang S. Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer. Int J Clin Exp Med. 2015;8:14701–17.PubMedPubMedCentral
5.
6.
Onwumeh J, Okwundu CI, Kredo T. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults. Cochrane Database Syst Rev. 2017;5:CD009818.PubMed
7.
Dhupkar P, Gordon N. Interleukin-2: old and new approaches to enhance immune-therapeutic efficacy. Adv Exp Med Biol. 2017;995:33–51.CrossRefPubMed
8.
Sheikhi A, Jafarzadeh A, Kokhaei P, Hojjat-Farsangi M. Whole tumor cell vaccine adjuvants: comparing IL-12 to IL-2 and IL-15. Iran J Immunol. 2016;13:148–66.PubMed
9.
Malaguarnera M, Ferlito L, Gulizia G, Di Fazio I, Pistone G. Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur J Clin Pharmacol. 2001;57:267–73.CrossRefPubMed
10.
Chi M, Dudek AZ. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res. 2011;21:165–74.CrossRefPubMed
11.
Roviello G, Zanotti L, Correale P, Gobbi A, Wigfield S, Guglielmi A, Pacifico C, Generali D. Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? Immunotherapy. 2017;9:25–32.CrossRefPubMed
12.
Mi D, Ren W, Yang K. Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis. Indian J Med Res. 2016;143:S1–S10.PubMedPubMedCentral
13.
Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004;57:358–65.CrossRefPubMed
14.
Manchikanti L, Benyamin RM, Helm S, Hirsch JA. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 3: systematic reviews and meta-analyses of randomized trials. Pain Physician. 2009;12:35–72.PubMed
15.
Changjie H, Zhiqiang L, Yongzi Z, Jianfeng H, Xiangping W. Transcatheter arterial infusion of interleukin-2 in the treatment of malignant pleural effusion (in Chinese). Guangxi Med J. 2001;23:770–72.
16.
Xiuzhi Y, Ruxi Y. 5Interleukin-2, cisplatin in combination with intracavitary treatment of malignant pleural effusion (in Chinese). Chin J Lung Cancer. 2001;4:391.
17.
Zhuo S, Hongxia B, Hanbing S, Yuhua K. Intrapleural injection of cisplatin and interleukin - 2 in the treatment of malignant pleural effusion (in Chinese). Modern Med J. 2004;32:259–61.
18.
Junyan W, Feihu J, Ning X, Zhixiang Y, Yuchuan H. Interleukin 2 combined with cisplatin in the treatment of malignant pleural effusion (in Chinese). Oncol Progress. 2005;3:401–2.
19.
Haiying X. Interleukin - 2 combined with cisplatin in the treatment of malignant pleural effusion (in Chinese). China Med Herald. 2009;6:57–8.
20.
Xiaoxia H, Fengying D. Comparison of the efficacy of intrapleural injection of cisplatin combined with interleukin-2 in the treatment of malignant pleural effusion (in Chinese). Int J Respir. 2009;29:669–71.
21.
Lizheng C, Miaozheng L. Observation and nursing of cisplatin combined with interleukin-II in the treatment of malignant pleural effusion (in Chinese). Int Med Health Guid News. 2009;15:88–9.
22.
Jinguang C, Ruifang W, Jin L, Jianguo L, Liqing A. Clinical observation of minimally invasive catheter drainage combined with drug injection in the treatment of malignant pleural effusion of lung cancer (in Chinese). Shanxi Med J. 2009;38:1026–7.
23.
Junfeng W, Ting Y, Mingxin T, Bo F. Clinical analysis of 41 cases of malignant pleural effusion treated by interleukin-2 combined with cisplatin via central venous catheters. Chin J Coal Ind Med. 2010;13:540–1.
24.
Jingping Z. Clinical observation of cisplatin and interleukin - 2 pleural cavity perfusion in treatment of lung cancer with malignant pleural effusion (in Chinese). J Med Theory Pract. 2010;23:7–9.
25.
Cheng X, Zaijun Z, Yuezheng H, Yeyuan W, Mingquan L. Clinical observation of treating malignant pleural effusion with intrathecal interleukin-2 and cisplatin (in Chinese). Cancer Prev Treat. 2010;23:211–3.
26.
Fang S, Jianping H, Bingxiang T. Observation on efficacy of micro-catheter drainage combined with intrapleural cisplatin and interleukin II treatment of malignant pleural effusion (in Chinese). Chin J Clin Oncol Rehabil. 2011;18:460–2.
27.
Xueling L. The therapeutic efficiency and nursing in the treatment of malignant pleural effusion by using restructured human interleukin-2 combined with cisplatin (in Chinese). Med J Chin People's Health. 2011;23:891–2.
28.
Yan Q, Xiaolei Z, Zhiqiang W, Ying C. Clinical observations on thoracic closed drainage combined with cisplatin and IL-2 for pleural effusion of pulmonary carcinoma (in Chinese). Henan Med Res. 2011;20:283–5.
29.
Li J. Interleukin - 2 combined with cisplatin in the treatment of malignant pleural effusion (in Chinese). Chin Commun Doctor. 2013;15:191–2.
30.
Lijie H, Qiuju Y, Ziying W. Curative effect of rIL-2 combined with cisplatin in the treatment of patients with malignant pleural effusions (in Chinese). Chin Pharm. 2014;17:1698–9.
31.
Miao H. Cisplatin combined with recombinant human interleukin-2 via pleural perfusion in the treatment of malignant pleural effusion (in Chinese). Chin Contin Med Educ. 2016;8:160–2.
32.
Baohua Y. A clinical analysis of treating pleural effusion (in Chinese). Clin J Chin Med. 2017;9:31–3.
33.
Biaoxue R, Xiguang C, Hua L, Wenlong G, Shuanying Y. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer. 2016;16:888.CrossRefPubMedPubMedCentral
34.
Minor DR, Moores SP, Chan JK. Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer. Gynecol Oncol Rep. 2017;22:43–4.CrossRefPubMedPubMedCentral
35.
Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, Li QJ, Li YS, Zhu B. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol. 2016;186:106–14.CrossRefPubMedPubMedCentral
36.
Bjermer L, Gronberg H, Roos G, Henriksson R. Interleukin-2-administration intravenously and intrapleurally in a patient with primary pulmonary adenocarcinoma. Cellular responses in peripheral blood, intrapleural fluid and bronchoalveolar lavage. Biotherapy. 1993;6:1–7.CrossRefPubMed
37.
Viallat JR, Boutin C, Rey F, Astoul P, Farisse P, Brandely M. Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer. 1993;71:4067–71.CrossRefPubMed
38.
Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion. Lung Cancer. 2017;104:70–4.CrossRefPubMed
39.
40.
Marta GN, Moraes FY, Leite ETT, Chow E, Cella D, Bottomley A. A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. Ann Palliat Med. 2017;6:S223–32.
41.
Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One. 2017;12:e0184360.CrossRefPubMedPubMedCentral
42.
Biaoxue R, Hua L, Wenlong G, Shuanying Y. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies. Oncotarget. 2016;7:86902–13.PubMedPubMedCentral
43.
Kostner AH, Ellegaard MB, Christensen IJ, Bastholt L, Schmidt H. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. Cancer Immunol Immunother. 2015;64:349–55.CrossRefPubMed
44.
Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001;24:287–93.CrossRefPubMed
45.
Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J ImmunoTher Cancer. 2014;2:26.CrossRef
Metadata
Title
Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients
Authors
Liping Han
Qiufang Jiang
Wei Yao
Tian Fu
Qingdi Zeng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4581-5

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Case report

Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report

Research article

Prognostic and clinicopathological significance of MLKL expression in cancer patients: a meta-analysis

Research article

Cancer patients’ knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study

Research article

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma

Research article

Projected lifetime cancer risks from occupational radiation exposure among diagnostic medical radiation workers in South Korea

Research article

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits